

Atty Docket No. 15280W-003000

PTO FAX NO.: 703-872-9306
571-273-0609

RECEIVED
CENTRAL FAX CENTER

FEB 22 2005

ATTENTION: Examiner Badio
Group Art Unit 1616

OFFICIAL COMMUNICATION**FOR THE PERSONAL ATTENTION OF****EXAMINER BADIO****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following documents, in re Application of Hyun K. Kim *et al.*, Application No. 09/526,855, filed March 17, 2000, for STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS, is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Transmittal Form

Number of pages being transmitted, including this page: 4

Dated: February 22, 2005


Linda Shaffer

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: (415) 576-0200, Fax: (415) 576-0300
60427099 v1

I hereby certify that this correspondence is being deposited by facsimile to
Art Unit 1616 at 703-872-9306

PATENT
Attorney Docket No.: 15280W-003000
Client Ref. No.: E-155-1999

On 2-22-05

TOWNSEND and TOWNSEND and CREW LLP

By: Gilda Shaffer

RECEIVED
CENTRAL FAX CENTER

FEB 22 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hyun K. Kim *et al.*

Application No.: 09/526,855

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION
OF 19-NORPROGESTERONE 1: 17-
ALPHA-SUBSTITUTED-11-BETA-
SUBSTITUTED-4-ARYL AND 21-
SUBSTITUTED 19-
NORPREGNADIENEDIONE AS NEW
ANTIPIGESTATIONAL AGENT

Customer No.: 20350

Confirmation No. 3023

Examiner: Barbara P. Badio

Technology Center/Art Unit: 1616

CORRECTED AMENDMENT AFTER
ALLOWANCE UNDER 37 CFR § 1.312(a)

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to a telephone inquiry of Examiner Badio in which it was noted that there was a typographical error in the "Amendments to the Specification" in the previously filed Amendment After Allowance, Applicants amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.